Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,813.08 +1,514.02 (+2.32%) CMC Crypto 200
1,368.12 -5.72 (-0.42%)
Novartis AG (NOVN.SW)
| Previous close | 92.62 |
| Open | 93.04 |
| Bid | 93.37 x 0 |
| Ask | 93.38 x 0 |
| Day's range | 93.04 - 93.85 |
| 52-week range | 79.21 - 94.52 |
| Volume | |
| Avg. volume | 3,236,359 |
| Market cap | 190.513B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 23.40 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.30 (3.56%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
- GlobeNewswire
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the initial acceptance period is expected to occur on 23 May 2024Additional statutory acceptance period is expected to end on 30 May 2024 at 24:00 hours CESTTransaction strengthens the Novartis pipeline in oncology, adding pelabresib, a late-stage BET inhibitor for myelofibrosis and tulmimetostat, an early-s
- GlobeNewswire
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the EHA Plenary SessionLatest data from the Kisqali®* NATALEE trial, including efficacy endpoints for patients with node-negative stage II and III HR+/HER2- early breast cancerNew radioligand therapy portfolio data supporting overall platform leadership and ongoing expansion in research infrastructure an
- GlobeNewswire
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
